EUVIMEDEUVIMED entdecken
Crossref

Development of small molecule–drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells

Takahiro Obara, Nanami Kawano, Kengo Tatsumi, Akira Katsuyama, Kohei Nakajima, Mikako Ogawa, Satoshi Ichikawa

Bioorganic & Medicinal Chemistry · 2024

DOI: 10.1016/j.bmc.2024.117773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Takahiro Obara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Science, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Glutamate Carboxypeptidase II, Antineoplastic Agents, Antigens, Surface. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Core Research for Evolutional Science and Technology, AMED, Hokkaido University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we have developedsmall molecule drug conjugates (SMDCs)consisting ofa prostate specific membrane antigen (PSMA) ligandand syringolin derivatives, which are potent proteasome inhibitors, to selectively deliver syringolin derivatives to prostate cancer cells. Two parent compounds were used for syringolin derivatives with different linkage sites. These SMDCs exhibited PSMA-expressing cell-selective cytotoxicity and they could potentially be used for safer treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsGlutamate Carboxypeptidase IIAntineoplastic AgentsAntigens, SurfaceHumansStructure-Activity RelationshipMolecular StructureDrug Screening Assays, AntitumorSmall Molecule LibrariesCell Line, TumorCell ProliferationDose-Response Relationship, DrugMaleProstatic NeoplasmsProteasome Endopeptidase Complex

Substanzen

Proteasome InhibitorsGlutamate Carboxypeptidase IIFOLH1 protein, humanAntineoplastic AgentsAntigens, SurfaceSmall Molecule LibrariesProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Science, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
  • Faculty of Pharmaceutical Science, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 06…

Förderung

  • Core Research for Evolutional Science and Technology
  • AMED
  • Hokkaido University
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science

Zitieren

APA

Obara, T., Kawano, N., Tatsumi, K., Katsuyama, A., Nakajima, K., Ogawa, M., & Ichikawa, S. (2024). Development of small molecule–drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117773

Vancouver

Obara T, Kawano N, Tatsumi K, Katsuyama A, Nakajima K, Ogawa M, et al. Development of small molecule–drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117773

BibTeX
@article{Obara2024,
  author = {Obara, Takahiro and Kawano, Nanami and Tatsumi, Kengo and Katsuyama, Akira and Nakajima, Kohei and Ogawa, Mikako and Ichikawa, Satoshi},
  title = {Development of small molecule–drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2024},
  doi = {10.1016/j.bmc.2024.117773}
}
Kostenlos starten →